ClinicalTrials.gg
CompletedNCT01605227COMET-1Updated Mar 14, 2018Results posted

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

A Phase 3 interventional study of cabozantinib and prednisone in Prostate Cancer, Castration Resistant Prostate Cancer and Pain, sponsored by Exelixis. Completed at 264 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,028
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.

Enrollment
2nd of 23
1,028 · median 33
Started
2012
with 5 others
Phase 3
4 of 23
1 open now
Registered
7th of 23
by date
Lead sponsor
6 of 23
Exelixis

Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 6 that started in 2012, is one of 4 in phase 3, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cabozantinib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.

03

Conditions studied

  • Prostate Cancer
  • Castration Resistant Prostate Cancer
  • Pain
  • Prostatic Neoplasms

Keywords

  • prostate cancer
  • castration resistant prostate cancer
  • bone pain
  • CRPC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of castration resistant prostate cancer (serum testosterone less than 50 ng/dL).
  • Evidence of bone related to prostate cancer on bone scans.
  • Received prior docetaxel (minimum cumulative dose of 225 mg/m2) and either abiraterone or MDV3100 treatment and has evidence of prostate cancer progression on each agent independently.
  • Maintenance of LHRH agonist or antagonist unless treated with orchiectomy.
  • Recovered from toxicities related to any prior treatments, unless the toxicities are clinically non significant or easily manageable.
  • Adequate organ and marrow function.
  • Capable of understanding and complying with the protocol requirements and signed the form.
  • Sexually active fertile patients and their partners must agree to use medically accepted methods of (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with cabozantinib.
  • Treatment with docetaxel, abiraterone, or MDV3100 in the last 2 weeks; or with any other type of cytotoxic or anticancer agent in the last 2 weeks.
  • Radiation within 4 weeks (excluded if to mediastinum) or radionuclide treatment within 6 weeks of randomization.
  • Known or cranial epidural disease.
  • Requires concomitant treatment, in therapeutic doses, with anticoagulants.
  • Requires chronic concomitant treatment of strong inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St. John's Wort).
  • Uncontrolled, significant intercurrent illness including, but not limited to, cardiovascular disorders, gastrointestinal disorders, active infections, non-healing wounds, recent surgery.
  • hematemesis or hemoptysis, or other signs indicative of pulmonary hemorrhage in the last 3 months, or history of other significant bleeding in the past 6 months.
  • Cavitating pulmonary lesion(s) or a lesion invading or encasing a major blood vessel.
  • > 500 ms within 7 days of randomization.
  • Unable to swallow capsules or tablets.
  • Previously-identified allergy or to components of the study treatment formulations.
  • Another diagnosis of requiring systemic treatment within 2 years of randomization.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,028 participants (actual)

Study arms

  • Experimental
    cabozantinib

    Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.

    Drug: cabozantinib

  • Active comparator
    prednisone

    Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.

    Drug: prednisone

Interventions

  • Tablets taken orally once-daily

    Also known as: XL184

  • Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred.

    Time frame: OS was measured from the time of randomization until 614 events, approximately 24 months after study start

Secondary outcomes

  1. Bone Scan Response (BSR)

    BSR is defined as \>=30% reduction in the bone scan lesion area (BSLA) compared with baseline. Confirmation of bone scan was not required for response or progression. Bone scans were evaluated by an independent radiology facility (IRF) for response.

    Time frame: BSR was measured at the end of Week 12 as determined by the IRF

Other outcomes

  1. Progression-free Survival (PFS)

    The exploratory analysis of PFS is the time from randomization to date of first documented radiographic progression (bone and/or soft tissue) according to the investigator's assessment or death. PFS was defined per mRECIST 1.1 and included evaluation of measurable, nonmeasurable, target and nontarget lesions. A Kaplan-Meier analysis was performed to estimate the median duration.

    Time frame: Duration of PFS was defined as time from the date of randomization to earlier of date of radiographic progression (bone/andor soft tissue) according to the investigator's assessment or death, assessed for up to approximately 24 months

07

Results

Posted Mar 14, 2018

Participant flow

First patient enrolled: 02 July 2012 (first subject randomized), Data cut off date: 07 July 2014

Participant flow — Overall Study
MilestoneCabozantinibPrednisone
Started682346
Completed6117
Not completed621329
Withdrew: Did not receive study treatment23
Withdrew: Adverse event22842
Withdrew: Progressive disease132128
Withdrew: Clinical deterioration227133
Withdrew: Lost to follow-up10
Withdrew: Protocol violation10
Withdrew: Physician decision97
Withdrew: Withdrawal by subject1814
Withdrew: Sponsor decision20
Withdrew: Started new therapy10
Withdrew: Subject decision01
Withdrew: Dose held >6 weeks01

Outcome measures

PrimaryOverall Survival (OS)

The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred.

Time frame:
OS was measured from the time of randomization until 614 events, approximately 24 months after study start
Reported as:
Median · months
Overall Survival (OS)
monthsCabozantinibPrednisone
Overall Survival (OS)11.0 (10.09 to 11.63)9.8 (9.00 to 11.53)
Statistical analysis
  • Cabozantinib vs Prednisone · Log Rank · p = 0.213 · Cox proportional hazard: 0.90 · 95% CI 0.76 to 1.06The Log-Rank test was stratified by prior cabazitaxel, baseline pain severity and baseline ECOG performance status.
SecondaryBone Scan Response (BSR)

BSR is defined as \>=30% reduction in the bone scan lesion area (BSLA) compared with baseline. Confirmation of bone scan was not required for response or progression. Bone scans were evaluated by an independent radiology facility (IRF) for response.

Time frame:
BSR was measured at the end of Week 12 as determined by the IRF
Reported as:
Number · percentage of participants
Bone Scan Response (BSR)
percentage of participantsCabozantinibPrednisone
Bone Scan Response (BSR)42 (38 to 46)3 (1 to 5)
Statistical analysis
  • Cabozantinib vs Prednisone · Cochran-Mantel-Haenszel · p = <0.001The Cochran-Mantel-Haenszel (CMH) Test was stratified by prior cabazitaxel, baseline pain severity and baseline ECOG performance status.
Other pre-specifiedProgression-free Survival (PFS)

The exploratory analysis of PFS is the time from randomization to date of first documented radiographic progression (bone and/or soft tissue) according to the investigator's assessment or death. PFS was defined per mRECIST 1.1 and included evaluation of measurable, nonmeasurable, target and nontarget lesions. A Kaplan-Meier analysis was performed to estimate the median duration.

Time frame:
Duration of PFS was defined as time from the date of randomization to earlier of date of radiographic progression (bone/andor soft tissue) according to the investigator's assessment or death, assessed for up to approximately 24 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCabozantinibPrednisone
Progression-free Survival (PFS)5.6 (5.49 to 5.62)2.8 (2.79 to 2.86)
Statistical analysis
  • Cabozantinib vs Prednisone · Log Rank · p = <0.001 · Hazard ratio (hr): 0.48 · 95% CI 0.40 to 0.57The Log-Rank Test was stratified by prior cabazitaxel, baseline pain severity, and baseline Eastern Cooperative Oncology Group Performance Status.

Adverse events

Collected over Up to 92 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib—420/681 (61.7%)675/681 (99.1%)
Prednisone—181/342 (52.9%)332/342 (97.1%)
Most frequent serious events
Showing 10 of 345
Most frequent serious events
EventCabozantinibPrednisone
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)52/68127/342
General physical health deteriorationGeneral disorders52/68122/342
Pulmonary embolismRespiratory, thoracic and mediastinal disorders42/6813/342
AnaemiaBlood and lymphatic system disorders32/68116/342
VomitingGastrointestinal disorders28/6816/342
PneumoniaInfections and infestations17/68112/342
Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/68112/342
NauseaGastrointestinal disorders23/6816/342
Bone painMusculoskeletal and connective tissue disorders15/68111/342
FatigueGeneral disorders20/6813/342
Most frequent other events
Showing 10 of 50
Most frequent other events
EventCabozantinibPrednisone
Decreased appetiteMetabolism and nutrition disorders407/68199/342
NauseaGastrointestinal disorders390/681102/342
DiarrhoeaGastrointestinal disorders349/68168/342
FatigueGeneral disorders338/681119/342
VomitingGastrointestinal disorders271/68167/342
Weight decreasedInvestigations237/68141/342
AstheniaGeneral disorders228/68163/342
ConstipationGastrointestinal disorders227/681100/342
AnaemiaBlood and lymphatic system disorders203/681111/342
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders200/6815/342

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CabozantinibPrednisoneTotal
<=18 years000
Between 18 and 65 years16597262
>=65 years517249766
Sex: Female, Male
Sex: Female, Male(Participants)CabozantinibPrednisoneTotal
Female000
Male6823461028
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CabozantinibPrednisoneTotal
American Indian or Alaska Native011
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American14620
White520265785
More than one race000
Unknown or Not Reported14674220
Region of Enrollment
Region of Enrollment(Participants)CabozantinibPrednisoneTotal
North America11963182
Europe528256784
Australia352762
Prior cabazitaxel (per CRF)
Prior cabazitaxel (per CRF)(Participants)CabozantinibPrednisoneTotal
Yes261132393
No421214635
Brief Pain Inventory (BPI) Item 3 (per CRF)
Brief Pain Inventory (BPI) Item 3 (per CRF)(Participants)CabozantinibPrednisoneTotal
<4389196585
≥4284148432
Missing9211
ECOG Performance Status (per CRF)
ECOG Performance Status (per CRF)(participants)CabozantinibPrednisoneTotal
0/1 (asymptomatic or symptomatic but ambulatory)605303908
2 (ambulatory but can't carry out work activities)7643119
Missing101
Opioid narcotic use within 24 hours (per solicited oploid CRF)
Opioid narcotic use within 24 hours (per solicited oploid CRF)(Participants)CabozantinibPrednisoneTotal
Count of participants454228682

8 further baseline measures are reported on the registry.

08

Study locations

264 sites
  • Birmingham, Alabama 35205, United States
  • Anchorage, Alaska 99508, United States
  • Phoenix, Arizona 85016, United States
  • Scottsdale, Arizona 85255, United States
  • Tucson, Arizona 85710, United States
  • Jonesboro, Arkansas 72401, United States
  • Duarte, California 91010, United States
  • Highland, California 92346, United States
  • La Jolla, California 92093, United States
  • Los Angeles, California 90033, United States
  • Montebello, California 90640, United States
  • Orange, California 92868, United States
  • Palo Alto, California 94301, United States
  • Rancho Mirage, California 92270, United States
  • Saint Helena, California 94574, United States
  • San Marcos, California 92069, United States
  • Vallejo, California 94589, United States
  • Aurora, Colorado 80045, United States
  • New Haven, Connecticut 06520, United States
  • Southington, Connecticut 06489, United States
  • Miami Beach, Florida 33140, United States
  • Ocala, Florida 34471, United States
  • Orlando, Florida 32806, United States
  • Tampa, Florida 33612, United States
  • Titusville, Florida 32796, United States
  • Wellington, Florida 33449, United States
  • West Palm Beach, Florida 33401, United States
  • Athens, Georgia 30607, United States
  • Atlanta, Georgia 30318, United States
  • Marietta, Georgia 30060, United States
  • Galesburg, Illinois 61401, United States
  • Niles, Illinois 60714, United States
  • Ames, Iowa 50010, United States
  • Sioux City, Iowa 51101, United States
  • Wichita, Kansas 67214, United States
  • Hazard, Kentucky 41701, United States
  • Louisville, Kentucky 40202, United States
  • Brewer, Maine 04412, United States
  • Baltimore, Maryland 21201, United States
  • Bethesda, Maryland 20817, United States
  • Towson, Maryland 21204, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02118, United States
  • Methuen, Massachusetts 01844, United States
  • Detroit, Michigan 48202, United States
  • Wyoming, Michigan 49509, United States
  • Minneapolis, Minnesota 55455, United States
  • Jefferson City, Missouri 65109, United States
  • Springfield, Missouri 65804, United States
  • Lincoln, Nebraska 68506, United States
  • Omaha, Nebraska 68130, United States
  • Hackensack, New Jersey 07601, United States
  • Lawrenceville, New Jersey 08648, United States
  • Albany, New York 12208, United States
  • Garden City, New York 11530, United States
  • New York, New York 10065, United States
  • Pinehurst, North Carolina 28374, United States
  • Bismarck, North Dakota 58501, United States
  • Cincinnati, Ohio 45219, United States
  • Columbus, Ohio 43221, United States
  • Portland, Oregon 97227, United States
  • Bryn Mawr, Pennsylvania 19010, United States
  • Hershey, Pennsylvania 17033, United States
  • Lancaster, Pennsylvania 17604, United States
  • Greenville, South Carolina 29615, United States
  • Chattanooga, Tennessee 37421, United States
  • Amarillo, Texas 79106, United States
  • Bedford, Texas 76022, United States
  • Houston, Texas 77024, United States
  • Laredo, Texas 78041, United States
  • San Antonio, Texas 78217, United States
  • Salt Lake City, Utah 84112, United States
  • Burlington, Vermont 05405, United States
  • Fairfax, Virginia 22031, United States
  • Newport News, Virginia 23601, United States
  • Spokane, Washington 99204, United States
  • Green Bay, Wisconsin 54311, United States
  • Albury, New South Wales 2640, Australia
  • Concord, New South Wales 2193, Australia
  • Darlinghurst, New South Wales 2010, Australia
  • Kogarah, New South Wales 2217, Australia
  • Port Macquarie, New South Wales 2444, Australia
  • Randwick, New South Wales 2031, Australia
  • Wahroonga, New South Wales 2076, Australia
  • Westmead, New South Wales 2145, Australia
  • South Brisbane, Queensland 4101, Australia
  • Southport, Queensland 4215, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Adelaide, South Australia 5000, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Hobart, Tasmania 7000, Australia
  • Bentleigh East, Victoria 3165, Australia
  • Box Hill, Victoria 3128, Australia
  • Wodonga, Victoria 3690, Australia
  • Perth, Western Australia 6000, Australia
  • Linz, 4010, Austria
  • Salzburg, 5020, Austria
  • Wein, 1100, Austria
  • Wien, 1090, Austria
  • Aalst, 9300, Belgium

Showing the first 100 of 264 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. PubMed 29272162 ↗
  • Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bogemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houede N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597. Epub 2016 Jul 11. PubMed 27400947 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Sep 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2018, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2012
First posted
May 24, 2012
Start
Jul 2012
Primary completionActual
Sep 2014
CompletionActual
Mar 2015
Results first posted
Mar 14, 2018
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01605227
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
May 24, 2012
Start date
Jul 2012
Primary completion
Sep 2014
Completion
Mar 2015
Results posted
Mar 14, 2018
Last update
Mar 14, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion